Abstract
Gastric cancer is the leading cause of cancer-related death worldwide, and treatment options include surgery and chemotherapy. Because of its prevalence, chemotherapy for gastric cancer treatment represents an active area of pharmacology research, and different small compounds have been used as single treatments or in combination therapy. Unfortunately, chemoresistance is a common phenomenon in gastric cancer cells, and the current arsenal of small compounds used in chemotherapy is not effective for long periods of treatment. Thus, to understand how gastric cancer cells develop chemoresistance and also to find new protein targets and small compounds for gastric cancer treatment, a systems pharmacology-based study was performed using the proteomic and small compounds-protein interaction data available for Homo sapiens. A major physical protein-protein and chemo-protein interaction (PPPI-PCPI) network was obtained, and five subnetworks representing different biological processes were observed. Interestingly, the small compounds currently used to treat gastric cancer converge on the same biological processes, potentially resulting in the development of chemoresistance. This analysis was followed by a network centrality study, which allows for selection of protein targets and/or small compounds, termed bottlenecks, that are defined as central nodes. The bottlenecks control the flow of biological information within the network, and their disruption can break the entire network into small components. From ten major bottlenecks observed within the network, seven bottlenecks represent new protein targets that are suitable for the development of new combinatory drug regimens for gastric cancer treatment.
Keywords: Drug convergence, Gastric cancer, network centralities, serine/threonine kinase inhibitors, small compound inhibitors, systems pharmacology, Aldehyde dehydrogenase 3, Fanconi anemia group C protein, Hepatocyte growth factor, Retinoid X receptor, Stathmin 1, Thymidylate synthase
Current Cancer Drug Targets
Title: A Systems Pharmacology Analysis of Major Chemotherapy Combination Regimens Used in Gastric Cancer Treatment: Predicting Potential New Protein Targets and Drugs
Volume: 11 Issue: 7
Author(s): J. O. Rosado, J. A.P. Henriques and D. Bonatto
Affiliation:
Keywords: Drug convergence, Gastric cancer, network centralities, serine/threonine kinase inhibitors, small compound inhibitors, systems pharmacology, Aldehyde dehydrogenase 3, Fanconi anemia group C protein, Hepatocyte growth factor, Retinoid X receptor, Stathmin 1, Thymidylate synthase
Abstract: Gastric cancer is the leading cause of cancer-related death worldwide, and treatment options include surgery and chemotherapy. Because of its prevalence, chemotherapy for gastric cancer treatment represents an active area of pharmacology research, and different small compounds have been used as single treatments or in combination therapy. Unfortunately, chemoresistance is a common phenomenon in gastric cancer cells, and the current arsenal of small compounds used in chemotherapy is not effective for long periods of treatment. Thus, to understand how gastric cancer cells develop chemoresistance and also to find new protein targets and small compounds for gastric cancer treatment, a systems pharmacology-based study was performed using the proteomic and small compounds-protein interaction data available for Homo sapiens. A major physical protein-protein and chemo-protein interaction (PPPI-PCPI) network was obtained, and five subnetworks representing different biological processes were observed. Interestingly, the small compounds currently used to treat gastric cancer converge on the same biological processes, potentially resulting in the development of chemoresistance. This analysis was followed by a network centrality study, which allows for selection of protein targets and/or small compounds, termed bottlenecks, that are defined as central nodes. The bottlenecks control the flow of biological information within the network, and their disruption can break the entire network into small components. From ten major bottlenecks observed within the network, seven bottlenecks represent new protein targets that are suitable for the development of new combinatory drug regimens for gastric cancer treatment.
Export Options
About this article
Cite this article as:
O. Rosado J., A.P. Henriques J. and Bonatto D., A Systems Pharmacology Analysis of Major Chemotherapy Combination Regimens Used in Gastric Cancer Treatment: Predicting Potential New Protein Targets and Drugs, Current Cancer Drug Targets 2011; 11 (7) . https://dx.doi.org/10.2174/156800911796798977
DOI https://dx.doi.org/10.2174/156800911796798977 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation Injury from the Anthracycline Antibiotics
Current Pharmaceutical Biotechnology Metabolic Functions of Myostatin and GDF11
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science MicroRNA Levels in Cervical Cancer Samples and Relationship with Lesion Grade and HPV Infection
MicroRNA Urtica dioica Extract Inhibits Cell Proliferation and Induces Apoptosis in HepG2 and HTC116 as Gastrointestinal Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Preparation and Optimization of Moxifloxacin Microspheres for Colon Targeted Delivery Using Quality by Design Approach: In Vitro and In Vivo Study
Current Drug Delivery Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors
Current Topics in Medicinal Chemistry <i>Brassica oleracea</i> var. <i>capitata f. alba</i>: A Review on its Botany, Traditional uses, Phytochemistry and Pharmacological Activities
Mini-Reviews in Medicinal Chemistry Rational Drug Design of Antineoplastic Agents Using 3D-QSAR, Cheminformatic, and Virtual Screening Approaches
Current Medicinal Chemistry Targetting Esophageal and Gastric Cancers with Monoclonal Antibodies
Current Topics in Medicinal Chemistry Screening Methods for Antioxidants-A Review
Mini-Reviews in Medicinal Chemistry Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Proteomic Analysis of Mitochondrial Proteins on the Mechanism of Apoptotic Under Amorphophallus konjac Tuber (KONJAC) Extracts in Gas tric Cancer Cell
Current Proteomics Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets Realizing the Potential of Health-Promoting Rosehips from Dogroses (Rosa sect. Caninae)
Current Bioactive Compounds ImmunoPET in Neoplasms of Gastrointestinal Tract, Liver and Pancreas in the XXIst Century: Bridging the Gap Between Diagnosis and Therapy
Reviews on Recent Clinical Trials Proline-Rich Peptides: Multifunctional Bioactive Molecules as New Potential Therapeutic Drugs
Current Protein & Peptide Science Antiproliferative Activities on Renal, Prostate and Melanoma Cancer Cell Lines of Sarcopoterium spinosum Aerial Parts and its Major Constituent Tormentic Acid
Anti-Cancer Agents in Medicinal Chemistry